Browsing by Author "Serra Elizalde, Violeta"
Now showing items 1-19 of 19
-
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Neeb, Antje; Herranz Martín, Nicolás; Arce Gallego, Sara; Buroni, Lorenzo; Yuan, Wei; Athie Cuervo, Alejandro; Casals, Teresa; Casanova Salas, Irene; Cordoba, Sarai; Castro, Natalia; González Rodríguez, Macarena; Morales Barrera, Rafael; Suárez Rodríguez, Cristina; Carles Galceran, Joan; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim; Miranda, Susana (Elsevier, 2021-02) -
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Dunn, Shanade; Eberlein, Cath; Yu, Jason; Ong, Swee Hoe; Yelland, Urs; Serra Elizalde, Violeta; Gris Oliver, Albert (Springer Nature, 2022-11-11) -
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
Capoluongo, Ettore Domenico; Pellegrino, B.; Califano, D.; Beltrame, L.; Serra Elizalde, Violeta; Llop Guevara, Alba; Scambia, Giovanni (Elsevier, 2022-10) -
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
Shah, Jennifer; Pueschl, Dana; Wubbenhorst, Bradley; Fan, Mengyao; Pluta, John; D’Andrea, Kurt; Llop Guevara, Alba; Serra Elizalde, Violeta; Balmaña Gelpí, Judith (Nature Portfolio, 2022-11-07) -
Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours
Groelly, Florian; Porru, Manuela; Zimmer, Jutta; Benainous, Hugo; De Visser, Yanti; Kosova, Anastasiya; Serra Elizalde, Violeta (Wiley, 2022-03-07) -
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Carreira, Suzanne; Porta, Nuria; Arce Gallego, Sara; Seed, George; Llop Guevara, Alba; Bianchini, Diletta; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim (American Association for Cancer Research, 2021-05-27) -
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
Wang, Yifan; Bernhardy, Andrea J.; Nacson, Joseph; Krais, John J.; Tan, Yin-Fei; Nicolas, Emmanuelle; Llop Guevara, Alba; Balmaña Gelpí, Judith; Serra Elizalde, Violeta (Springer Nature, 2019-12-11) -
Clinical consequences of BRCA2 hypomorphism
Castells-Roca, Laia; Gutierrez Enriquez, Sara; Bonache Real, Sandra; Bogliolo, Massimo; Carrasco López, Estela; Aza-Carmona, Miriam; Montalban Canudas, Gemma; Cruz Zambrano, Cristina; Llop Guevara, Alba; Serra Elizalde, Violeta; Diez Gibert, Orland; Balmaña Gelpí, Judith; Saura Manich, Cristina (Nature Research, 2021-09-09) -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Palafox Sánchez, Marta; Monserrat Vicente, Laia; Gonzalez-Perez, Abel; Antunes de Melo Oliveira, Ana Mafalda; Òdena, Andreu; Sanchez-Guixe, Monica; Capelan Rodríguez, Marta; Azaro Pedrazzoli, Analía Beatriz; Rodriguez Ferreiro, Olga; Guzman Torres, Marta; Grueso Gragera, Judit; Viaplana Donato, Cristina; Hernandez Losa, Javier; Arribas López, Joaquin Vicente; Nuciforo, Paolo Giovanni; Serra Elizalde, Violeta; Villacampa Javierre, Guillermo; Bellet Ezquerra, Meritxell; Saura Manich, Cristina; Dienstmann, Rodrigo (Nature Portfolio, 2022-09-07) -
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
Pellegrino, B.; Musolino, Antonio; Llop Guevara, Alba; Serra Elizalde, Violeta; De Silva, P.; Hlavata, Z. (Elsevier, 2020-02-01) -
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Serra Camprubi, Queralt; Verdaguer Mata, Helena; Oliveros, Winona; Lupión-Garcia, Núria; Llop Guevara, Alba; Molina, Cristina; Vila Casadesus, Maria; Querol Paños, Jessica; Yáñez, Mariana; Escudero Iriarte, Carmen; Escorihuela Baez, Marta; Nuciforo, Paolo Giovanni; Vivancos Prellezo, Ana; Serra Elizalde, Violeta; Arribas López, Joaquin Vicente; Tabernero Caturla, Josep; Peiro Sales, Sandra; Macarulla Mercadé, Teresa; Tian, Tian V; Bernadó Morales, Cristina; Arenas Lahuerta, Enrique Javier; Frigola Rissech, Joan; Fabregat Franco, Carles; Castet, Florian; Miquel Aymar, Josep Maria (American Association for Cancer Research, 2023-01-17) -
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Serra Elizalde, Violeta; Wang, Anderson T.; Castroviejo Bermejo, Marta; Polanska, Urszula M.; Palafox Sánchez, Marta; Llop Guevara, Alba; Guzman Torres, Marta; Rodriguez Ferreiro, Olga; Grueso Gragera, Judit; Arribas López, Joaquin Vicente; Cortés Castan, Javier; Cruz Zambrano, Cristina; Balmaña Gelpí, Judith; Saura Manich, Cristina; Herencia Ropero, Andrea (American Association for Cancer Research, 2022-10-15) -
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Li, Qing; Jiang, Baishan; Guo, Jiaye; Shao, Hong; Del Priore, Isabella; Chang, Qing; Palafox Sánchez, Marta; Serra Elizalde, Violeta (American Association for Cancer Research, 2022-02-01) -
Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity
Wright, Sarah Christine Elisabeth; Vasilevski, Natali; Serra Elizalde, Violeta; Rodon Ahnert, Jordi; Eichhorn, Pieter Johan Adam (MDPI, 2021-04) -
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer
Dinami, Roberto; Pompili, Luca; Petti, Eleonora; Porru, Manuela; D’Angelo, Carmen; Di Vito, Serena; Serra Elizalde, Violeta (Wiley, 2023-01-11) -
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, Lidia; Duran-Frigola, Miquel; Palafox Sánchez, Marta; Scaltriti, Maurizio; Razavi, Pedram; Arribas López, Joaquin Vicente; Serra Elizalde, Violeta; Gris Oliver, Albert; Bellet Ezquerra, Meritxell (BMC, 2020-09-09) -
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Garrido-Castro, Ana Christina; Barroso-Sousa, Romualdo; Guo, Hao; Ciruelos, Eva; Bermejo, Begoña; Serra Elizalde, Violeta; Rodon Ahnert, Jordi; Saura Manich, Cristina (BMC, 2020-11-02) -
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
Rodriguez, María Jimena; Perrone, María Cecilia; Riggio, Marina; Palafox Sánchez, Marta; Salinas, Valeria; Elia, Andres; Serra Elizalde, Violeta (Nature Portfolio, 2023-02-15) -
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Lahiguera, Álvaro; Hyroššová, Petra; Figueras, Agnès; Garzón, Diana; Moreno, Roger; Soto-Cerrato, Vanessa; Serra Elizalde, Violeta (Wiley, 2020-06-08)